InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Browse the complete record of transactions filed by Ordentlich Peter, Directeur Scientifique. Officer active across 2 companies, notably Syndax Pharmaceuticals Inc. In total, 5 reports have been published. Activity tracked since 31 January 2022. The latest transaction was filed on 15 February 2023 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 条申报中的 5 条
Peter Ordentlich is the Chief Scientific Officer at Syndax Pharmaceuticals Inc. He is responsible for leading the company's research and development initiatives, ensuring innovation and advancement in pharmaceutical technologies. Peter Ordentlich plays a key role in the scientific direction of the company, contributing to its success in the biopharmaceutical field.